New horizons in joint health: Bioiberica’s latest venture with IFA Celtics and Faes Farma
02 Feb 2024 --- Life science company Bioiberica has entered two strategic ventures in the mobility arena — with IFA Celtics in Mexico and will continue its alliance with Faes Farma in Spain.
“We strongly believe that strategic alliances are the powerhouse of transformative progress in the human health industry, including the joint health and mobility space,” says Joan Bassa, human health director at Bioiberica.
“We aim to empower the healthcare evolution by supporting our growing network of valued partners with research and insights to propel innovation. Our most recent alliances with IFA Celtics and Faes Farma is just another example of how we’re championing collaboration to drive change in the category.”
Branded ingredients
The collaborations have inspired the R&D of advanced joint health formulations with Bioiberica’s Collavant n2 native (undenatured) type II collagen and Mobilee, a hyaluronic acid matrix ingredient.
The company’s most recent venture with IFA Celtics led to the development of Hialoflex, which was positioned for joint health in Mexico. The formula combines Collavant n2 (40 mg), a native (undenatured) type II collagen and Mobilee (80 mg), a patented combination of hyaluronic acid, polysaccharides and collagen.
“As a trusted brand that serves many physicians, who are key stakeholders in the local market – it’s important for us to have confidence in the ingredients we choose for our finished products. Quality, science and safety always guide our decisions, and that’s exactly why we chose Bioiberica’s Collavant n2 and Mobilee solutions,” says Dr. Julio Morfin, medical director at IFA Celtics.
“But we didn’t team up with the company for its ingredient offering alone. A renowned name in the joint health sector, with 20-plus years of experience in the field, our collaboration saw us benefit from the support of Bioiberica’s experienced marketing and technical teams, 360-degree view of the landscape and expert-led training sessions.”
Meanwhile, Dermial, Bioiberica’s hyaluronic acid ingredient made with essential components of human skin, has potential in developing products for the growing nutricosmetics space in supplements, functional food and cosmetics. It has regenerative, antioxidant and moisturizing properties that treat and prevent skin aging.
Collagen brands
Bioiberica is strengthening its foothold in Latin America and building on its reputation in Europe. Its partner, Faes Farma partnered with them to extend its product range in the region by incorporating Collavant n2 as a key ingredient in its Vitanatur Multicollagen supplement.
The capsules, launched in Spain in May 2023, contain 40 mg Collavant n2, eggshell membrane (containing type I, V and X collagen), hyaluronic acid, magnesium and vitamins C, K2 and D3 to deliver support to joints, bones and skin.
“We’re experts in collagen. However, bringing a new product to market is never risk-free, especially in a fast-growing and competitive landscape, like the mobility arena”, comments Marina Escudero Garcia, product manager healthcare and consumer at Faes Farma.
“With Bioiberica’s support and understanding of the local market, we were able to develop and launch Vitanatur Multicollagen with speed, ease and confidence.”
Bioiberica’s Collavant n2 native type II collagen is featured in other Spanish brands, including Colnatur by Laboratorios Ordesa and Aritcolageno Nativo Plus by Reig Jofre.
By Inga de Jong
